CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
AG-920 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04513652
NCT04513652Phase 3Completed
CompareCT.gov

A Randomized, Double-Masked, Vehicle-Controlled, Parallel Evaluation of the Local Anesthetic Effect of Articaine Sterile Topical Ophthalmic Solution

American Genomics, LLC·interventional·Posted Aug 14, 2020·Updated Sep 28, 2022

In Brief

A Phase 3 clinical trial evaluating AG-920 and Placebo for Anesthesia, Local. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This is a Phase 3, randomized, placebo-controlled, double masked, parallel design study in healthy subjects performed in the US. It is designed to evaluate the safety and anesthetic efficacy of AG-920 Sterile Topical Ophthalmic Solution.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia, Local
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedAug 14, 2020
Enrollment StartSep 3, 2020
Primary CompletionSep 30, 2020
Study CompletionDec 17, 2020
TodayJul 2, 2026
Enrollment to primary: 27 daysPosted 5.9 years ago

Interventions

AG-920drug

AG-920 Sterile Topical Ophthalmic Solution

Placebodrug

Placebo Topical Ophthalmic Solution